Response to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics”

Response to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics”

Triangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin.

Bibliographic Details
Main Authors: Bovijn, J, Krebs, K, Chen, C-Y, Boxall, R, Censin, JC, Ferreira, T, Pulit, SL, Glastonbury, CA, Laber, S, Millwood, IY, Lin, K, Li, L, Chen, Z, Milani, L, Smith, GD, Walters, RG, Mägi, R, Neale, BM, Lindgren, CM, Holmes, MV
Format: Journal article
Language:English
Published: American Association for the Advancement of Science 2021

Similar Items

Similar Items